| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
CANCER |
1 Laboratory of AnatomoPathology, Erasmus University Hospital, Free University of Brussels (ULB), Brussels, Belgium
2 Laboratory of Histopathology, Faculty of Medicine, Free University of Brussels (ULB), Brussels, Belgium
3 Department of Surgery, Jules Bordet Institute, Free University of Brussels (ULB), Brussels, Belgium
4 Institute of Molecular Animal Breeding, Gene Centre, Ludwig-Maximilians-University, Munich, Germany
5 Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians-University, Munich, Germany
6 Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel
7 Laboratory of Logical and Numerical Systems, Faculty of Applied Sciences, Free University of Brussels (ULB), Brussels, Belgium
8 Digestive Health Centre, University of Virginia Health System, Charlottesville, Virginia, USA
9 Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Correspondence to:
Correspondence to:
R Kiss, Laboratory of Histopathology, Faculty of Medicine, Université Libre de Bruxelles, 808 route de Lennik, 1070 Brussels, Belgium;
rkiss{at}ulb.ac.be
Background and aims: Galectins are ß-galactoside binding proteins. This ability may have a bearing on cell adhesion and migration/proliferation in human colon cancer cells. In addition to galectins-1 and -3 studied to date, other members of this family not investigated in detail may contribute to modulation of tumour cell features. This evident gap has prompted us to extend galectin analysis beyond the two prototypes. The present study deals with the quantitative determination of immunohistochemical expression of galectin-8 in normal, benign, and malignant human colon tissue samples and in four human colon cancer models (HCT-15, LoVo, CoLo201, and DLD-1) maintained both in vitro as permanent cell lines and in vivo as nude mice xenografts. The role of galectin-8 (and its neutralising antibody) in cell migration was investigated in HCT-15, LoVo, CoLo201, and DLD-1 cell lines.
Methods: Immunohistochemical expression of galectin-8 and its overall ability to bind to sugar ligands (revealed glycohistochemically by means of biotinylated histochemically inert carrier bovine serum albumin with 
- and ß-D-galactose, -D-glucose, and lactose derivatives as ligands) were quantitatively determined using computer assisted microscopy. The presence of galectin-8 mRNA in the four human colon cancer cell lines was examined by reverse transcriptase-polymerase chain reaction. In vitro, cellular localisation of exogenously added galectin-8 in the culture media of these colon cancer cells was visualised by fluorescence microscopy. In vitro galectin-8 mediated effects (and the influence of its neutralising antibody) on migration levels of living HCT-15, LoVo, CoLo201, and DLD-1 cells were quantitatively determined by computer assisted phase contrast microscopy.
Results: A marked decrease in immunohistochemical expression of galectin-8 occurred with malignancy development in human colon tissue. Malignant colon tissue exhibited a significantly lower galectin-8 level than normal or benign tissue colon cancers; those with extensive invasion capacities (T3–4/N+/M+) harboured significantly less galectin-8 than colon cancers with localised invasion capacities (T1–2/N0/M0). The four experimental models (HCT-15, LoVo, CoLo201, and DLD-1) had more intense galectin-8 dependent staining in vitro than in vivo. Grafting the four experimental human colon cancer models onto nude mice enabled us to show that the immunohistochemical expression of galectin-8 was inversely related to tumour growth rate. In vitro, galectin-8 reduced the migration rate of only those human experimental models (HCT-15 and CoLo201) that exhibited the lowest growth rate in vivo.
Conclusions: Expression of galectin-8 correlated with malignancy development, with suppressor activity, as shown by analysis of clinical samples and xenografts. In vitro, only the two models with low growth rates were sensitive to the inhibitory potential of this galectin. Future investigations in this field should involve fingerprinting of these newly detected galectins, transcending the common focus on galectins-1 and -3.
Keywords: colon cancer; dysplasia; galectin-8; integrins; cell migration
Abbreviations: AS, average speed; CCD, coupled charge device; CRD, carbohydrate recognition domain; LI, labelling index; MOD, mean optical density; MRDO, maximum relative distance to the origin; RT-PCR, reverse transcriptase-polymerase chain reaction
This article has been cited by other articles:
|
|
 |
|
  M. Del Rio, F. Molina, C. Bascoul-Mollevi, V. Copois, F. Bibeau, P. Chalbos, C. Bareil, A. Kramar, N. Salvetat, C. Fraslon, et al. Gene Expression Signature in Advanced Colorectal Cancer Patients Select Drugs and Response for the Use of Leucovorin, Fluorouracil, and Irinotecan J. Clin. Oncol., March 1, 2007; 25(7): 773 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Arbel-Goren, Y. Levy, D. Ronen, and Y. Zick Cyclin-dependent Kinase Inhibitors and JNK Act as Molecular Switches, Regulating the Choice between Growth Arrest and Apoptosis Induced by Galectin-8 J. Biol. Chem., May 13, 2005; 280(19): 19105 - 19114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Delbrouck, H.-J. Gabius, H. Kaltner, C. Decaestecker, R. Kiss, and S. Hassid Expression Patterns of Galectin-1 and Galectin-3 in Nasal Polyps and Middle and Inferior Turbinates in Relation to Growth Regulation and Immunosuppression Arch Otolaryngol Head Neck Surg, June 1, 2003; 129(6): 665 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Levy, D. Ronen, A. D. Bershadsky, and Y. Zick Sustained Induction of ERK, Protein Kinase B, and p70 S6 Kinase Regulates Cell Spreading and Formation of F-actin Microspikes Upon Ligation of Integrins by Galectin-8, a Mammalian Lectin J. Biol. Chem., April 11, 2003; 278(16): 14533 - 14542. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
